Spots Global Cancer Trial Database for Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Official Title: A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Study ID: NCT03430518

Conditions

HER2-Negative Metastatic Breast Cancer

Recurrent Ovarian Cancer

Interventions

Durvalumab

Eribulin

Study Description

Brief Summary: This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.

Detailed Description: STUDY SUMMARY Study Duration: Accrual will take place over the course of 16 months. Patients will be treated until unacceptable toxicity or disease progression (expected on average for 6 months) and then followed for one year thereafter. Objectives: Phase I: To determine the the recommended phase II dose of eribulin in combination with Durvalumab This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab. If two or more out of 6 patients experience a dose limiting toxicity (DLT) at dose level I or II, the dose level below that level will be considered the RP2D. If all 3 patients enter dose level-I and experience DLT, the study will be terminated. If the highest level has been reached and \< 33% of patients have experienced DLT, that will be considered the RP2D.